These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 6822737)

  • 1. Neutralization of influenza virus by normal human sera: mechanisms involving antibody and complement.
    Beebe DP; Schreiber RD; Cooper NR
    J Immunol; 1983 Mar; 130(3):1317-22. PubMed ID: 6822737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralization of vesicular stomatitis virus (VSV) by human complement requires a natural IgM antibody present in human serum.
    Beebe DP; Cooper NR
    J Immunol; 1981 Apr; 126(4):1562-8. PubMed ID: 6259260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of the alternative complement pathway by EBV and the viral envelope glycoprotein, gp350.
    Mold C; Bradt BM; Nemerow GR; Cooper NR
    J Immunol; 1988 Jun; 140(11):3867-74. PubMed ID: 2836501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of selective complement deficiency on the rate of neutralization of enveloped viruses by human sera.
    Leddy JP; Simons RL; Douglas RG
    J Immunol; 1977 Jan; 118(1):28-34. PubMed ID: 187701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions of a nonneutralizing IgM antibody and complement in parainfluenza virus neutralization.
    Vasantha S; Coelingh KL; Murphy BR; Dourmashkin RR; Hammer CH; Frank MM; Fries LF
    Virology; 1988 Dec; 167(2):433-41. PubMed ID: 2849234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralization of Epstein-Barr virus by nonimmune human serum. Role of cross-reacting antibody to herpes simplex virus and complement.
    Nemerow GR; Jensen FC; Cooper NR
    J Clin Invest; 1982 Nov; 70(5):1081-91. PubMed ID: 6290536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-independent neutralization of vesicular stomatitis virus by human complement. II. Formation of VSV-lipoprotein complexes in human serum and complement-dependent viral lysis.
    Mills BJ; Beebe DP; Cooper NR
    J Immunol; 1979 Dec; 123(6):2518-24. PubMed ID: 227957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of C3 deposition on solid-phase bound immune complexes by lactoferrin.
    Kievits F; Kijlstra A
    Immunology; 1985 Mar; 54(3):449-56. PubMed ID: 3844370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible mechanisms of the first step of the classical complement activation pathway: binding and activation of C1.
    Füst G; Medgyesi GA; Rajnavölgyi E; Csécsi-Nagy M; Czikora K; Gergely J
    Immunology; 1978 Dec; 35(6):873-84. PubMed ID: 104923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depressed classical complement pathway activities in chronic lymphocytic leukaemia.
    Füst G; Czink E; Minh D; Miszlay Z; Varga L; Hollán SR
    Clin Exp Immunol; 1985 Jun; 60(3):489-95. PubMed ID: 4017286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The requirement of specific anticapsular IgG for killing of Haemophilus influenzae by the alternative pathway of complement activation.
    Tarr PI; Hosea SW; Brown EJ; Schneerson R; Sutton A; Frank MM
    J Immunol; 1982 Apr; 128(4):1772-5. PubMed ID: 6977569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Staphylococcus aureus opsonization mediated via the classical and alternative complement pathways. A kinetic study using MgEGTA chelated serum and human sera deficient in IgG and complement factors C1s and C2.
    Verbrugh HA; Van Dijk WC; Peters R; Van Der Tol ME; Peterson PK; Verhoef J
    Immunology; 1979 Mar; 36(3):391-7. PubMed ID: 108204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of immune precipitation by purified components of the alternative pathway.
    Naama JK; Holme E; Hamilton E; Whaley K
    Clin Exp Immunol; 1985 Apr; 60(1):169-77. PubMed ID: 3159522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies of the mechanism of bacterial resistance to complement-mediated killing. V. IgG and F(ab')2 mediate killing of E. coli 0111B4 by the alternative complement pathway without increasing C5b-9 deposition.
    Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
    J Immunol; 1983 Nov; 131(5):2563-9. PubMed ID: 6355296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of supraphysiologic levels of C1-inhibitor on the classical, lectin and alternative pathways of complement.
    Nielsen EW; Waage C; Fure H; Brekke OL; Sfyroera G; Lambris JD; Mollnes TE
    Mol Immunol; 2007 Mar; 44(8):1819-26. PubMed ID: 17101176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C1- inactivator: its efficiency as a regulator of classical complement pathway activation by soluble IgG aggregates.
    Doekes G; van Es LA; Daha MR
    Immunology; 1983 Jun; 49(2):215-22. PubMed ID: 6852866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of classical pathway components during alternative pathway--modulated immune complex aggregation: the role of C1 INH.
    Gronski P; Bodenbender L; Kanzy EJ; Seiler FR
    Behring Inst Mitt; 1984 Nov; (76):29-41. PubMed ID: 6335396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement-mediated inhibition of immune precipitation. I. Role of the classical and alternative pathways.
    Schifferli JA; Woo P; Peters DK
    Clin Exp Immunol; 1982 Mar; 47(3):555-62. PubMed ID: 6979442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of immune precipitation by complement.
    Hong K; Takata Y; Sayama K; Kozono H; Takeda J; Nakano Y; Kinoshita T; Inoue K
    J Immunol; 1984 Sep; 133(3):1464-70. PubMed ID: 6747294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Control of immune complexes by the classical pathway.
    Whaley K; Ahmed AE
    Behring Inst Mitt; 1989 Jul; (84):111-20. PubMed ID: 2529842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.